Seres Therapeutics (MCRB)
(Delayed Data from NSDQ)
$1.00 USD
+0.04 (4.08%)
Updated Sep 13, 2024 04:00 PM ET
After-Market: $0.99 -0.01 (-0.92%) 7:58 PM ET
2-Buy of 5 2
F Value B Growth B Momentum C VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$1.00 USD
+0.04 (4.08%)
Updated Sep 13, 2024 04:00 PM ET
After-Market: $0.99 -0.01 (-0.92%) 7:58 PM ET
2-Buy of 5 2
F Value B Growth B Momentum C VGM
Zacks News
Earnings Preview: Seres Therapeutics (MCRB) Q4 Earnings Expected to Decline
by Zacks Equity Research
Seres Therapeutics (MCRB) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
5 Medical Outperformers That Might Lose Steam in 2021
by Zacks Equity Research
Here we discuss some biotech stocks, which are up this year so far but might not be good additions to your portfolio.
Seres Therapeutics (MCRB) Reports Q3 Loss, Lags Revenue Estimates
by Zacks Equity Research
Seres Therapeutics (MCRB) delivered earnings and revenue surprises of -50.00% and -84.51%, respectively, for the quarter ended September 2020. Do the numbers hold clues to what lies ahead for the stock?
Nasdaq's Best Third Quarter in 10 Years: Best ETFs & Stocks
by Sanghamitra Saha
The tech-heavy Nasdaq index posted its best third quarter in 10 years this year.
Biotech Stock Roundup: BMY & REGN Q2 Earnings, Gilead NDA for Coronavirus Drug
by Zacks Equity Research
The biotech sector remains in focus with earnings, regulatory and other pipeline updates.
Do Options Traders Know Something About Seres Therapeutics (MCRB) Stock We Don't?
by Zacks Equity Research
Investors need to pay close attention to Seres Therapeutics (MCRB) stock based on the movements in the options market lately.
Earnings Preview: Seres Therapeutics (MCRB) Q2 Earnings Expected to Decline
by Zacks Equity Research
Seres Therapeutics (MCRB) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Seres Therapeutics (MCRB) in Focus: Stock Moves 10.8% Higher
by Zacks Equity Research
Seres Therapeutics (MCRB) saw a big move last session, as its shares jumped nearly 11% on the day, amid huge volumes.
Implied Volatility Surging for Seres Therapeutics (MCRB) Stock Options
by Zacks Equity Research
Investors need to pay close attention to Seres Therapeutics (MCRB) stock based on the movements in the options market lately.
Implied Volatility Surging for Seres Therapeutics (MCRB) Stock Options
by Zacks Equity Research
Investors need to pay close attention to Seres Therapeutics (MCRB) stock based on the movements in the options market lately.
Seres Therapeutics (MCRB) Reports Q1 Loss, Tops Revenue Estimates
by Zacks Equity Research
Seres Therapeutics (MCRB) delivered earnings and revenue surprises of 3.45% and 2.24%, respectively, for the quarter ended March 2020. Do the numbers hold clues to what lies ahead for the stock?
Seres Therapeutics (MCRB) May Report Negative Earnings: Know the Trend Ahead of Q1 Release
by Zacks Equity Research
Seres Therapeutics (MCRB) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Seres Therapeutics (MCRB) Reports Q4 Loss, Tops Revenue Estimates
by Zacks Equity Research
Seres Therapeutics (MCRB) delivered earnings and revenue surprises of 3.85% and 11.76%, respectively, for the quarter ended December 2019. Do the numbers hold clues to what lies ahead for the stock?
Seres Therapeutics (MCRB) Reports Q3 Loss, Tops Revenue Estimates
by Zacks Equity Research
Seres Therapeutics (MCRB) delivered earnings and revenue surprises of 11.54% and 5.16%, respectively, for the quarter ended September 2019. Do the numbers hold clues to what lies ahead for the stock?
Seres Therapeutics, Inc. (MCRB) Shares March Higher, Can It Continue?
by Zacks Equity Research
As of late, it has definitely been a great time to be an investor in Seres Therapeutics, Inc. (MCRB).
Seres Therapeutics (MCRB) Reports Q2 Loss, Tops Revenue Estimates
by Zacks Equity Research
Seres Therapeutics (MCRB) delivered earnings and revenue surprises of 42.86% and 21.78%, respectively, for the quarter ended June 2019. Do the numbers hold clues to what lies ahead for the stock?
Seres Therapeutics (MCRB) May Report Negative Earnings: Know the Trend Ahead of Q2 Release
by Zacks Equity Research
Seres Therapeutics (MCRB) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Seres Therapeutics (MCRB) Reports Q1 Loss, Lags Revenue Estimates
by Zacks Equity Research
Seres Therapeutics (MCRB) delivered earnings and revenue surprises of -27.91% and -15.00%, respectively, for the quarter ended March 2019. Do the numbers hold clues to what lies ahead for the stock?
Seres Therapeutics (MCRB) in Focus: Stock Moves 6.7% Higher
by Zacks Equity Research
Seres Therapeutics (MCRB) saw a big move last session, as its shares jumped nearly 7% on the day, amid huge volumes.
Seres Therapeutics (MCRB) Reports Q3 Loss, Misses Revenue Estimates
by Zacks Equity Research
Seres Therapeutics (MCRB) delivered earnings and revenue surprises of 5.26% and -61.35%, respectively, for the quarter ended September 2018. Do the numbers hold clues to what lies ahead for the stock?
Seres Therapeutics Sees Hammer Chart Pattern: Time to Buy?
by Zacks Equity Research
Seres Therapeutics has been struggling lately, but the selling pressure may be coming to an end soon.
Seres Therapeutics (MCRB) Reports Q2 Loss, Lags Revenue Estimates
by Zacks Equity Research
Seres Therapeutics (MCRB) delivered earnings and revenue surprises of 1.45% and -11.56%, respectively, for the quarter ended June 2018. Do the numbers hold clues to what lies ahead for the stock?
Seres Therapeutics (MCRB) Catches Eye: Stock Gains 9.2%
by Zacks Equity Research
Seres Therapeutics, Inc. (MCRB) shares rose a little above 9% in the last trading session.
Seres Therapeutics' Stock Up as SER-109 Moves to Phase III
by Zacks Equity Research
Shares of Seres Therapeutics, Inc. (MCRB) went up by more than 5% on Monday, after it announced that its lead pipeline candidate, SER-109, has moved into late-stage development for the treatment of multiply recurrent C. difficile infection.
Why Seres Therapeutics (MCRB) Might Surprise This Earnings Season
by Zacks Equity Research
Seres Therapeutics (MCRB) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.